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Abstract
Background: In the Mediterranean basin, Leishmania infantum is a major cause of disease in dogs, which are
frequently co-infected with other vector-borne pathogens (VBP). However, the associations between dogs with
clinical leishmaniosis (ClinL) and VBP co-infections have not been studied. We assessed the risk of VBP infections in
dogs with ClinL and healthy controls.
Methods: We conducted a prospective case-control study of dogs with ClinL (positive qPCR and ELISA antibody for
L. infantum on peripheral blood) and clinically healthy, ideally breed-, sex- and age-matched, control dogs (negative
qPCR and ELISA antibody for L. infantum on peripheral blood) from Paphos, Cyprus. We obtained demographic
data and all dogs underwent PCR on EDTA-blood extracted DNA for haemoplasma species, Ehrlichia/Anaplasma
spp., Babesia spp., and Hepatozoon spp., with DNA sequencing to identify infecting species. We used logistic
regression analysis and structural equation modelling (SEM) to evaluate the risk of VBP infections between ClinL
cases and controls.
Results: From the 50 enrolled dogs with ClinL, DNA was detected in 24 (48%) for Hepatozoon spp., 14 (28%) for
Mycoplasma haemocanis, 6 (12%) for Ehrlichia canis and 2 (4%) for Anaplasma platys. In the 92 enrolled control
dogs, DNA was detected in 41 (45%) for Hepatozoon spp., 18 (20%) for M. haemocanis, 1 (1%) for E. canis and 3 (3%)
for A. platys. No Babesia spp. or “Candidatus Mycoplasma haematoparvum” DNA was detected in any dog. No
statistical differences were found between the ClinL and controls regarding age, sex, breed, lifestyle and use of
ectoparasitic prevention. A significant association between ClinL and E. canis infection (OR = 12.4, 95% CI: 1.5–106.0,
P = 0.022) was found compared to controls by multivariate logistic regression. This association was confirmed using
SEM, which further identified that younger dogs were more likely to be infected with each of Hepatozoon spp. and
M. haemocanis, and dogs with Hepatozoon spp. were more likely to be co-infected with M. haemocanis.
Conclusions: Dogs with ClinL are at a higher risk of co-infection with E. canis than clinically healthy dogs. We
recommend that dogs diagnosed with ClinL should be tested for E. canis co-infection using PCR.
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Background
Canine leishmaniosis, caused by the protozoan parasite
Leishmania infantum, is transmitted by a phlebotomine
sand fly vector [1] and is endemic in Central and South
America, Asia and several countries of the Mediterranean
basin. An estimated 2.5 million dogs are infected with L.
infantum in south-west Europe alone [2]. This potentially
fatal protozoal infection of dogs and humans is an ideal
example of the “One Health” approach to disease since
dogs are the major reservoir of infection for humans [3].
In addition, an increasing number of canine leishmaniosis
cases are being reported in non-endemic European coun-
tries, such as the UK and Germany, due to pet travel and
importation of dogs from endemic areas, making leishma-
niosis an emerging disease in these countries [4–6]. There
is a risk that it might become endemic in such countries if
future climate conditions support the life-cycle of a
suitable vector.
Dogs with clinical leishmaniosis (ClinL) are often
concurrently infected with multiple pathogens, which
are often vector-borne, such as Ehrlichia canis, the
causative agent for canine monocytic ehrlichiosis, Ana-
plasma platys, Babesia vogeli and Hepatozoon canis,
resulting in an unpredictable incubation period, atypical
clinical outcome and poorer prognosis, compared with
dogs infected with L. infantum alone [7, 8]. These vec-
tor-borne pathogens (VBP) are transmitted by different
vectors to dogs, such as Rhipicephalus sanguineus (for A.
platys, E. canis and H. canis), Ixodes ricinus (for Ana-
plasma phagocytophilum), Ixodes spp. ticks (for Borrelia
burgdorferi) and mosquitoes (for Dirofilaria immitis) [9].
While it has been suggested that leishmaniosis is a predis-
posing factor for infection with other pathogens in dogs,
this has not been investigated to date [8, 10].
The aim of this case-control study was to investigate
the hypothesis that dogs with ClinL are at greater risk
for VBP infections than clinically healthy dogs. In
addition, besides the commonly used logistic regression
analyses for case-control studies [11], we performed
structural equation modelling (SEM), which is an ad-
vancement of traditional regression approaches, allowing
direct, indirect and co-variance relationships to be
assessed simultaneously. The SEM has recently been
employed in veterinary studies [12].
Methods
Study design and populations
Through a case-control study design, we evaluated if
dogs with ClinL are at a greater risk than healthy
controls for VBP infections including Babesia spp.,
“Candidatus Mycoplasma haematoparvum” (CMhp),
Ehrlichia/Anaplasma spp., Hepatozoon spp., and M.
haemocanis. All dogs presented as clinical patients to a
veterinary centre in Paphos, Cyprus, an area with high
prevalence of L. infantum in dogs [13] and endemic for
canine VBPs [14].
Eligible cases included dogs naturally infected with
ClinL which were diagnosed based on the presence of
clinical signs associated with L. infantum infection, and
enrolled in the final statistical analysis if they were
positive on both quantitative PCR (qPCR) on peripheral
blood and serum antibodies for L. infantum. We
attempted to match controls to the cases by age, sex and
breed as well as, if possible, by lifestyle and the use of
ectoparasitic prevention. For ClinL crossbreed dogs, the
controls were dogs of similar size and dog group (e.g.
terrier, toy or hound group) to the case dog. The control
dogs were apparently clinically healthy, and were en-
rolled in the final statistical analysis if they were negative
by both qPCR and antibody serology for L. infantum on
peripheral blood.
Data on age, sex (male or female), breed (pedigree or
crossbreed), lifestyle (outdoors or mainly indoors), use of
ectoparasitic prevention (use or no use) and clinical
signs were recorded for each dog. All dogs were exam-
ined by the same veterinarian author (CA) and classified
as clinically healthy or suffering from ClinL, following
The LeishVet Group Guidelines [15]. Exclusion criteria
for enrolment in this study included prior vaccination or
treatment for leishmaniosis, dogs undergoing therapy
with immunosuppressives/chemotherapeutics or dogs
less than 6 months old.
Laboratory tests
We obtained blood samples of approximately 2–4 ml in
plain and EDTA blood tubes by venepuncture from each
dog. The EDTA blood tubes were centrifuged; plasma
samples were obtained and transferred in a separate
tube. All tubes were frozen at -20 °C until transported
on dry ice to the Department of Pathobiology and Popu-
lation Sciences, The Royal Veterinary College, University
of London, Hatfield, Hertfordshire, UK. For the PCRs,
DNA was extracted from 200 μl of EDTA blood using a
commercial kit GenEluteTM Blood Genomic DNA Kit
(Sigma-Aldrich, Dorset, UK) according to the manufac-
turer’s instructions. During extraction, nuclease-free
water was used as a negative extraction control. The
DNA was eluted with 50 μl of nuclease free water and
stored at -20 °C until transported on dry ice to Diagnos-
tic Laboratories, Langford Vets, University of Bristol,
UK, for testing.
In order to assess the presence of amplifiable DNA,
the absence of PCR inhibitors and correct assay setup,
the qPCRs for Leishmania spp. [16], Babesia spp. [17],
CMhp and M. haemocanis [18] were duplexed with an
internal amplification control (glyceraldehyde-3-phos-
phate dehydrogenase gene), and a threshold cycle (Ct)
value of < 30 was used as a cut-off for indication of
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acceptable DNA. Any samples with Ct values greater
than or equal to 30 were excluded from the study due to
insufficient quantity/quality of DNA. Conventional PCR
assays, as previously described, were used to detect
infection with Ehrlichia/Anaplasma spp. [19] and
Hepatozoon spp. [20]. For each PCR assay, DNA from
known infected dogs and nuclease-free water were used
as positive and negative controls, respectively.
All samples that yielded positive results with the Ehrli-
chia/Anaplasma spp. PCR assay and 1/3 of the positive
Hepatozoon spp. samples (a mixture of ClinL cases and
controls) were purified using the NucleoSpin PCR and
Gel Clean-up kit (Macherey-Nagel, Düren, Germany) ac-
cording to the manufacturer’s instructions, quantified
with a Qubit™ fluorometer (Thermo Fisher Scientific,
Paisley, UK) and submitted for DNA sequencing at
DNA Sequencing and Services (College of Life Sciences,
University of Dundee, Scotland), in both directions using
the same primers as those used for the PCR. The for-
ward and reverse DNA sequences were then assembled,
and a consensus sequence was searched against the
NCBI database using BLAST (www.ncbi.nlm.nih.gov/
BLAST) to identify the infecting species.
For the L. infantum serology, sera from cases and
controls were transported on dry ice to the Departament
de Medicina i Cirurgia Animals, Facultat de Veterinària,
Universitat Autònoma de Barcelona, Barcelona, Spain. A
L. infantum enzyme-linked immunosorbent assay
(ELISA), as previously described, was used [21]. Each
ELISA also included a calibrator serum sample from a
dog infected by L. infantum as confirmed by IFAT (IFI
Megascreen FLUOLEISH inf, Diagnostik Megacor,
Hörbranz, Austria), a commercially available ELISA
(Esteve Veterinary Laboratories, Dr Esteva S.A, Barcelona,
Spain) and a rapid immunomigratory test (Speedleish,
Virbac, La Seyne sur Mer, France). The ELISA also in-
cluded a positive control serum sample from a dog with
confirmed L. infantum infection by IFAT and demonstrat-
ing clinical signs associated with Leishmania infection, as
well as a negative control serum sample from a cat that
was resident in the UK where L. infantum is not endemic.
Results were quantified as ELISA units (EU) relative to the
calibrator (arbitrarily set at 100 EU). The positive cut-off
value had previously been established at 35 EU (mean + 4
standard deviations of values from 80 dogs from a non-
endemic area).
Statistical analysis
We calculated the sample size to allow the identification
of risk for VBP co-infection in dogs with ClinL as
follows. On the basis of the admission frequencies for
VBPs in the study’s veterinary centre and previously pub-
lished data [14, 22–24] the expected proportion of control
dogs being exposed to VBPs was estimated at 5%. The
power calculation was performed using the on-line
EpiTools epidemiological calculator (http://epitools.ausvet.-
com.au). A sample size of 50 dogs with ClinL and 50
controls was calculated, when the testing hypothesis
was set with an odds ratio of 6, a power of 80% and
confidence level at 95%. To strengthen the statistical
power, we used approximately a 1:2 ratio for matching.
We compared the continuous variable (age) between
ClinL cases and controls with the Mann-Whitney test and
categorical variables (sex, breed, lifestyle, use of ectopara-
sitic prevention, positivity for A. platys, positivity for E.
canis, positivity for Hepatozoon spp. and positivity for M.
haemocanis) with the Chi-square test. Independent vari-
ables that yielded P-values of < 0.1 in a univariable analysis
Fig. 1 Comparison of VBPs detected by PCR and sequencing between dogs with ClinL (n = 50) and healthy control (n = 92). Abbreviations: VBP,
vector-borne pathogen; ClinL, clinical leishmaniosis; A. platys, Anaplasma platys; E. canis, Ehrlichia cani; M. haemocanis, Mycoplasma haemocanis
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were then tested in a multivariable logistic regression ana-
lysis. Within the final multivariable models a P-value
≤0.05 was considered statistically significant for inclusion.
Descriptive statistics and multivariable logistic regression
analysis was carried out using SPSS for Windows (version
22.0; SPSS Inc., Chicago, IL, USA).
We constructed a SEM that reflected the two hypothe-
sised mechanisms associated with ClinL and VBPs infec-
tion statuses in domestic dogs: (i) causal effects of host
characteristics; and (ii) pathogen interrelationships. We
modelled the host characteristics as variables that pre-
dicted VBPs status, except ClinL which was controlled
for in the sampling design. To estimate VBP interrela-
tionships, including potential pathogen-facilitation, we
included pathogen-pathogen covariance in the model.
We followed Kline [25] and Rosseel [26], and more re-
cent package advancements available through the R
package lavaan (www.lavaan.ugent.be) to check align-
ment with SEM assumptions. Model fit was assessed
using a chi-square statistic, and additionally scrutinized
using a root mean square error of approximation and a
comparative fit index, as recommended by Kline [25].
We used a diagonally weighted least squares SEM
estimator method, which is appropriate for endogenous
categorical variables [25, 26]. We present standardised
coefficients and covariances enabling comparison
among coefficient effect sizes [25, 26]. All SEM ana-
lyses were undertaken in the program R version 3.1.2
(www.r-project.org) using the lavaan [26] package.
Results
From March 2013 to April 2014, 53 dogs with ClinL and
103 dog controls were screened for eligibility. We
excluded three dogs with ClinL; two were ELISA-
positive but qPCR-negative and one was qPCR-positive
but ELISA-negative for L. infantum. From the controls
dogs 11 were excluded; nine were qPCR-positive and
two were ELISA-positive for L. infantum. The age of the
142 dogs enrolled in the case-control study ranged from
1 to 12 years (median 5.6 years, interquartile range
8 years) and 105 (74%) were pedigree. The most com-
mon breeds were Segugio Italiano, Cocker Spaniel,
German Shepherd, Beagle and German Shorthair
Pointer.
From the 50 enrolled dogs with ClinL, DNA was
detected in 24 (48%) for Hepatozoon spp., 14 (28%) for
M. haemocanis, 6 (12%) for E. canis and 2 (4%) for A.
platys. In the 92 enrolled control dogs, DNA was
detected in 41 (45%) for Hepatozoon spp., 18 (20%)
for M. haemocanis, 1 (1%) for E. canis and 3 (3%) for
A. platys (Fig. 1). Only H. canis was identified following
sequencing of Hepatozoon spp. PCR-positive samples. No
Babesia spp. or “Candidatus Mycoplasma haematopar-
vum” DNA was detected in any dog. Table 1 summarizes
the characteristics and the PCR results for the VBPs
tested.
Using multivariable logistic regression analysis, a
significant association between ClinL and E. canis
infection [odds ratio = 12.4, 95% confidence interval
(CI): 1.5–106.0, P = 0.022] compared to control dogs
was found. We did not identify any association for A.
platys, Hepatozoon spp. and M. haemocanis between
the two groups. There were no statistically significant
differences between the ClinL cases and controls in
terms of age, sex, breed, lifestyle, and use of ectopara-
sitic prevention.
Table 1 Characteristics of the study dog groups and PCR/
sequencing results for the VBPs tested. All dogs tested negative
on quantitative PCR for Babesia spp. and “Candidatus
Mycoplasma haematoparvum”. The species of A. platys and E.
canis were identified following sequencing of PCR products
derived from generic Ehrlichia/Anaplasma PCR testing
Characteristic No. of cases
ClinL (%) (n = 50)
Control (%)
(n = 92)
Age in years
Median 3 4
Interquartile range 3.3 3.0
Sex
Male 24 (48) 50 (54)
Female 26 (52) 42 (46)
Lifestyle
Outoors 35 (70) 68 (74)
Mainly indoors 15 (30) 24 (26)
Ectoparasitic prevention
Used 17 (34) 38 (41)
Not used 33 (66) 54 (69)
Breed
Pedigree 35 (70) 70 (76)
Crossbreed 15 (30) 22 (24)
A. platys
Positive 2 (4) 3 (3)
Negative 48 (96) 89 (97)
E. canis
Positive 6 (12) 1 (1)
Negative 44 (88) 91 (99)
Hepatozoon spp.
Positive 24 (48) 41 (45)
Negative 26 (52) 51 (55)
M. haemocanis
Positive 14 (28) 18 (20)
Negative 36 (72) 74 (80)
Abbreviations: VBP, vector-borne pathogen; ClinL, clinical leishmaniosis;
A. platys, Anaplasma platys; E. canis, Ehrlichia canis; M. haemocanis,
Mycoplasma haemocanis
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The SEM supported four main associations among
variables (Fig. 2, Table 2). Dogs with ClinL were more
likely to be co-infected with E. canis, younger dogs were
more likely to be infected with each of Hepatozoon spp.
and M. haemocanis, although only a trend was
identified for the latter, and a trend existed for co-in-
fections between Hepatozoon spp. and M. haemocanis to
occur. The SEM showed that there was otherwise negli-
gible evidence of determinants of, or correlations among,
VBPs.
Discussion
In this first comprehensive case-control study assessing
the risk of VBP co-infection in dogs with leishmaniosis,
our key finding shows that dogs with ClinL are 12 times
(CI: 1.5–106.0, P = 0.022) more likely to be co-infected
with E. canis compared to healthy controls. This further
supports the concept of synergism between L. infantum
and E. canis during co-infection in dogs in which, as pre-
vious studies have suggested, there are more commonly
clinical signs (e.g. lymphadenomegaly, splenomegaly, epi-
staxis, weight loss) [27], more severe haematological
changes (e.g. reduced platelet aggregation response, in-
creased activated partial thromboplastin time) [7, 27–29]
and hindered clinical improvement during treatment [30]
compared to dogs with either ClinL or canine monocytic
ehrlichiosis alone.
The pathogenesis behind the speculated synergetic
action of L. infantum and E. canis in dogs has not been
investigated. Due to the zoonotic nature of canine
leishmaniosis there have been extensive studies on the
immunopathology of this disease, and it is the best
understood canine VBP [9]. It is widely accepted that L.
infantum infection promotes a mixed Type 1 T helper
(Th1) and Th2 response that will determine the clinical
outcome [31], with increased immunosuppressive
substances such as interleukin 10, transforming growth
factor β and prostaglandin E2 prevailing in dogs with
ClinL [32–35]. The suppression of the immune system
by these substances could enable reactivation of a previ-
ously subclinical E. canis infection or facilitate the estab-
lishment of a new E. canis infection in dogs. While little
is known regarding the immunopathology of canine
monocytic ehrlichiosis, there is evidence of downregula-
tion of major histocompatibility complex (MHC) class II
molecules in a macrophage cell line infected with E.
canis compared with uninfected macrophages [36]. This
downregulation of MHC could impact upon Leishmania
infection outcome as MHC class II antigen presentation
is likely to be an important mechanism in generating an
effective cell mediated response to L. infantum. Further-
more, MHC Class II genotype has been associated with
Leishmania specific antibody level and parasite load but
not with clinical outcome [37].
In humans there is a well-established synergism
between leishmaniasis and human immunodeficiency
virus (HIV) [38], with Leishmania causing a more rapid
progression to AIDS [39] and HIV increasing the risk of
developing fatal visceral leishmaniasis [40]. The immu-
nopathology of this synergistic relationship has been
Fig. 2 Structural equation model showing predictors of vector-borne co-infection (except Leishmania infantum), and pathogen covariance
(including L. infantum). Values represent standardised coefficients among variables. Single headed arrows represent directional/causal relationships
and double headed arrows covariance relationships among pathogens. For image clarity the coefficients of host characteristics predicting
pathogens are listed next to each host characteristic. In all cases, except age, variables are binomial (0 or 1) with 1 equal to male, outside,
ectoparasitic prevention use, pedigree and positive pathogen status. Significant relationships (P≤ 0.05) denoted by bold font and trending
relationships (P < 0.1) denoted by *. Abbreviations: A. platys, Anaplasma platys; E. canis, Ehrlichia canis; M. haemocanis, Mycoplasma haemocanis.
Note: Values represent standardised coefficients among variables. Single headed arrows represent directional/causal relationships and double
headed arrows covariance relationships among pathogens. For image clarity the coefficients of host characteristics predicting pathogens are listed
next to each host characteristic. In all cases, except age, variables are binomial (0 or 1) with 1 equal to male, outside, ectoparasitic prevention use,
pedigree and positive pathogen status. Significant relationships (P ≤ 0.05) denoted by bold font and trending relationships (P < 0.1) denoted by *.
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documented to arise due to the co-existence of these two
pathogens in macrophages, as well as other cells, trigger-
ing complex mechanisms involving cellular-signalling and
cytokine production [38, 41, 42]. A similar pathogenesis
mechanism could potentially exist between L. infantum
and E. canis in dogs, since both microorganisms infect
monocytes and macrophages. This hypothetical mechan-
ism is supported by the findings of our clinical case-
control study in which an association with ClinL was only
found with E. canis co-infection, but not with A.
platys, Hepatozoon spp. or M. haemocanis that infect
predominantly platelets, neutrophils and erythrocytes,
Table 2 Structural equation model statistical output showing host characteristics predicting infection status for co-infecting pathogens
(except Leishmania infantum), and the covariance among pathogens (including L. infantum), in domestic dogs. In all cases, except age,
variables are binomial (0 or 1) with 1 equal to male, outside, ectoparasitic prevention use, pedigree and positive pathogen status
Standardised
coefficient/covariance
z-value P-value
E. canis
Age -0.081 -0.790 0.429
Sex -0.034 -0.391 0.696
Lifestyle 0.042 0.351 0.726
Ectoparasite prevention 0.099 0.749 0.454
Breed 0.055 0.634 0.526
A. platys
Age 0.113 1.187 0.235
Sex -0.069 -0.789 0.430
Lifestyle 0.114 1.445 0.148
Ectoparasitic prevention -0.003 -0.028 0.978
Breed -0.151 -1.161 0.246
Hepatozoon spp.
Age -0.173 -1.966 0.049
Sex -0.054 -0.623 0.534
Lifestyle 0.046 0.399 0.690
Ectoparasitic prevention 0.010 0.079 0.937
Breed 0.007 0.071 0.943
M. haemocanis
Age -0.127 -1.650 0.099*
Sex 0.030 0.348 0.728
Lifestyle 0.096 0.921 0.357
Ectoparasitic prevention -0.034 -0.287 0.774
Breed -0.046 -0.439 0.661
Covariances
E. canis - Leishmaniosis 0.243 2.303 0.021
A. platys - Leishmaniosis 0.020 0.223 0.824
Hepatozoon spp. - Leishmaniosis 0.034 0.393 0.694
M. haemocanis - Leishmaniosis 0.099 1.115 0.265
E. canis - A. platys -0.031 -0.889 0.374
E. canis - Hepatozoon spp. -0.028 -0.312 0.755
E. canis - M. haemocanis -0.046 -0.598 0.550
A. platys - Hepatozoon spp. -0.098 -1.130 0.258
A. platys - M. haemocanis 0.072 0.647 0.517
Hepatozoon spp. - M. haemocanis 0.158 1.761 0.078*
Abbreviations: A. platys, Anaplasma platys; E. canis, Ehrlichia canis; M. haemocanis, Mycoplasma haemocanis
Significant relationships (P ≤ 0.05) denoted by bold font and trending relationships (P < 0.1) denoted by *
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respectively [43–45]. Equally, other mechanisms could
orchestrate the pathogenesis of the suspected synergistic
relationship between L. infantum and E. canis in dogs.
Therefore, further studies are needed to investigate how
the co-infection of these two pathogens potentially affect
the dog’s immune response.
Although, our study is not a cross-sectional epidemio-
logical research project, and the dog population re-
cruited is heavily biased by the inclusion and exclusion
criteria, it does provide information for the prevalence
of the various VBP tested in the area of Paphos in
Cyprus, especially since 65% (92/142) of the samples we
collected were from apparently healthy dogs. In the
studied population of 142 dogs there is a noticeably high
prevalence of Hepatozoon spp. (46%), with H. canis
being the only species identified by sequencing, as well
as a reasonably high prevalence for M. haemocanis
(23%). Similar prevalences have been reported for Hepa-
tozoon spp. and haemoplasmas in the cat population of
this island [20], suggesting that the patterns of infection
for these two VBP in both the dogs and cats of Cyprus
are possibly driven by comparable processes. The preva-
lence for E. canis of 5% (7/142), and for A. platys of 4%
(5/142) in this canine population, are similar to those re-
ported in dogs from other Mediterranean countries [46].
The use of SEM strengthens the findings of our study
by confirming the association found between ClinL and
E. canis and allowed us to simultaneously investigate the
effects of demographic, lifestyle and breed on VBP infec-
tion, and the associations between the different VBP.
Two additional findings were made. The first one was
that dogs infected with Hepatozoon spp. were more
likely to be infected with M. haemocanis and, to the
authors’ knowledge, this is the first time such an associ-
ation has been reported. This is probably due to the fact
that both VBP are suspected to have the same vector
R. sanguineus, despite their different routes of trans-
mission: host ingestion of the tick for Hepatozoon
spp. transmission and a tick bite for M. haemocanis
transmission [44, 47]. Secondly, SEM showed that
younger dogs were more likely to be infected with
each of Hepatozoon spp. and M. haemocanis, which is
in agreement with a previous study on dogs infected
with canine haemoplasmas from other Mediterranean
countries [48] and could suggest that young animals
are more intensively exposed to such VBP.
Limitations of our study include selection and obser-
ver bias as this is a case-control study, and the
geographical restriction of only including one district of
Cyprus. Furthermore, the control dogs were recruited
on the basis of being clinically healthy, thus they might
not be representative of the general canine population.
A multicentre prospective longitudinal study design with
follow-up monitoring from birth until death would be
ideal, but difficult to implement. Even so, the adequate
sample size and conclusions which were based on statis-
tical analysis employing different methodologies should
allow some generalisation of our findings to other coun-
tries with similar environmental conditions and canine
VBP prevalence as Paphos, Cyprus. Studies in the future
over longer time periods would be beneficial to investi-
gate the possibility of seasonal effects and to determine
if the prognosis of leishmaniosis is different when dogs
are also co-infected with E. canis and other VBPs.
Our finding, that dogs with ClinL are at increased risk
of E. canis infection compared to healthy dogs, could
impact upon the diagnostic and monitoring management
of canine leishmaniosis. We recommend that dogs
diagnosed with ClinL should be tested for E. canis co-
infection using PCR on EDTA peripheral blood [49].
Quantitative serological testing can be considered for
the diagnosis of active E. canis infection but should be
interpreted appropriately [46]. Whilst we did not per-
form any follow up on the dogs with ClinL, to further
investigate if there is an ongoing increased risk of co-
infections during or after the treatment period, we
recommend E. canis PCR testing on EDTA peripheral
blood if there is clinical or haematological deterioration,
such as thrombocytopenia, despite the dog receiving the
appropriate anti-Leishmania treatment.
If a dog with ClinL is diagnosed with concurrent E.
canis infection, we recommend simultaneous treatment
of both infections. For E. canis, the treatment of choice
is oral doxycycline at 5 mg/kg twice daily or 10 mg/kg
once daily for 4 weeks [46] and for leishmaniosis the
appropriate treatment protocol should be based on the
clinical stage following The LeishVet Group Guidelines
[15]. Furthermore, dogs with ClinL should receive regu-
lar and effective protective topical insecticide repellent
to prevent infection with E. canis by R. sanguineus and
avoid transmission of L. infantum to sand flies.
Conclusions
We showed that dogs with ClinL are 12 times more
likely to be co-infected with E. canis than clinically
healthy dogs in Cyprus. These findings are of a value in
the diagnosis and management of leishmaniosis in dogs.
We recommend that dogs diagnosed with ClinL should
be tested for E. canis co-infection using PCR. Further
studies should be targeted in investigating the under-
lying pathology of this association.
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